New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 7, 2014
06:21 EDTMYGNMyriad Genetics upgraded to Neutral from Underperform at Credit Suisse
Credit Suisse upgraded Myriad Genetics to Neutral based on strong quarterly results and the Crescendo acquisition that adds diversification and accretion. Price target raised to $29 from $18.
News For MYGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
07:51 EDTMYGNTESARO, Myriad Genetics announce companion diagnostics collaboration
Subscribe for More Information
November 19, 2014
07:08 EDTMYGNCrescendo data shows Vectra DA is better predictor of joint damage in RA
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use